Argobio launches Laigo Bio with €11.5 million seed financing to advance novel membrane protein degradation platform
03/12/2025
- Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Laigo Bio
- Financing co-led by Kurma Partners and Curie Capital
- Laigo Bio is the second of eight Argobio-founded companies to achieve a seed financing to date
Paris, France - 04 December 2025. Argobio Studio, the launch platform for Europe’s best medicinal science, announced today the launch of Laigo Bio, with €11.5 million seed financing from a strong European investor syndicate. The financing was co-led by Kurma Partners and Curie Capital, and includes Cancer Research Horizons, Angelini Ventures, Eurazeo, the Oncology Bridge Fund at the Oncode Institute, and ROM Utrecht region, in addition to Argobio.
Laigo Bio, headquartered in Utrecht, the Netherlands, is pioneering novel and highly differentiated therapies using its proprietary SureTAC™ precision membrane protein degradation platform. The proceeds from the seed financing will be used to advance its oncology and immunology drug candidate pipeline.
“We are pleased to take additional seed funding for Laigo Bio which we have supported since its inception. Its differentiated targeted membrane protein degradation platform enables access to disease mechanisms previously viewed as undruggable, holding tremendous potential benefit for human health. This new funding allows us to pivot into immunology, an emerging therapeutic area for TPD,” said Neill Moray Mackenzie, Partner and Entrepreneur in Residence at Argobio, and Chairman of Laigo Bio.
“I am thrilled to welcome our new investors. Argobio has been instrumental in the creation and pre-seed funding of Laigo Bio; thanks to their vision and collaborative support, we are now able to advance further our novel approach to developing protein degradation drug candidates,” said Matthew Baker, Chief Executive Officer of Laigo Bio. “Our SureTAC platform is able to stimulate selective degradation of membrane-bound targets, which we believe could lead to more transformative therapies for patients with autoimmune and inflammatory diseases.”
“This is our second company launch this year, which highlights the expertise and ability of our team of operational venture builders to rapidly translate transformational science into globally competitive biotech ventures. We now have a portfolio of eight companies that we have founded from the most cutting-edge European science,” added Thierry Laugel, Chairman of the Management Board of Argobio and Managing Partner at Kurma Partners.
Another Argobio company, Elkedonia, announced an €11.25 million seed financing in June 2025 to advance discovery of its first-in-class non-hallucinogenic neuroplasticity enhancing antidepressant candidates for treatment-resistant depression.
Laigo Bio (www.laigobio.com), an early stage biotech company based in the Netherlands, is the first company to leverage E3 ligase internalization for the selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTAC™ platform creates bispecific antibodies that target the optimal pair of E3 ligase and disease-causing target to stimulate ubiquitination and lysosomal degradation of the target protein with a high degree of specificity. Degradation of the target protein achieves deeper inhibition of disease pathways, while sparing the desirable functions of the target cell.
Argobio Studio (www.argobiostudio.com) is the launch platform for Europe’s best science. We turn cutting-edge science into globally competitive European companies pioneering breakthrough therapeutics for patients around the world. As operational venture builders, we reduce execution risk by co-founding, investing, and embedding our experienced, collaborative team, accelerating development with industrial rigor and speed toward value-creating milestones.
